Trinity Capital Inc. Provides $20 Million in Growth Capital to Emboline, Inc. to Advance Interventional Heart Procedure Technology
Rhea-AI Summary
Trinity Capital (Nasdaq: TRIN) committed $20 million in growth capital to Emboline to support commercial preparation for the Emboliner embolic protection catheter. The Emboliner uses a flexible mesh to capture and remove debris during minimally invasive heart procedures.
Emboline completed patient enrollment in the PROTECT H2H IDE clinical trial; funds will scale manufacturing, expand the team, and support clinical and regulatory milestones ahead of commercial launch.
Positive
- $20 million committed to fund commercial readiness and scaling
- Completed patient enrollment in the PROTECT H2H IDE trial
Negative
- Regulatory approval and commercial launch remain contingent on clinical data and IDE outcomes
- Commercial rollout dependent on successful manufacturing scale-up and milestone execution
News Market Reaction – TRIN
In the Mar 11 session, TRIN declined 0.60%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Growth capital deal | Positive | -1.3% | Committed $50M in growth capital to Dwelly for UK expansion. |
| Feb 25 | Earnings results | Positive | +2.5% | Reported record 2025 investment income, NII, NAV, and AUM growth. |
| Feb 03 | Earnings preview | Positive | +0.5% | Released preliminary Q4 and 2025 estimates for NII and NAV with low non-accruals. |
| Feb 02 | Growth capital deal | Positive | -2.9% | Committed £25M of growth capital to Motorway to support UK growth. |
| Jan 28 | Credit rating update | Positive | +0.5% | Morningstar DBRS confirmed investment grade rating at BBB (low) with Positive trend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
TRIN has seen positive price alignment with earnings and rating news, while recent growth capital deployment headlines (Dwelly, Motorway) coincided with short-term price declines.
In the past few months, Trinity Capital has combined strong financial performance with active growth capital deployment. Record 2025 results featured total investment income of $293.7M and net investment income of $144.1M, alongside higher NAV and expanding AUM. The company has announced multiple growth capital commitments, including $50M to Dwelly and £25M to Motorway, and received a confirmed investment grade rating of BBB (low) with a Positive trend. Today’s Emboline financing continues this pattern of portfolio expansion in specialized verticals.
Key Terms
emboliner embolic protection catheter medical
minimally invasive heart procedures medical
investigational device exemption (ide) regulatory
clinical trial medical
regulatory approval regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Emboline's proprietary Emboliner® Embolic Protection Catheter is designed to help make minimally invasive heart procedures safer by capturing and removing debris that could otherwise reach the brain and other vital organs. The Emboliner is composed of a flexible, conforming mesh that allows normal blood flow while providing protection during procedures. The company recently completed patient enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, advancing its efforts to generate the clinical data needed for regulatory approval and the commercial launch of the Emboliner system.
"We're proud to partner with the Emboline team as they advance their mission to reduce strokes and other complications associated with heart procedures," said Rob Lake, Senior Managing Director at Trinity Capital. "The team's passion and dedication to improving patient safety is inspiring, and we're excited to support them as they expand access to the Emboline system."
"We are entering an important phase as we prepare for the commercial introduction of the Emboliner system," said Scott Russell, President and CEO of Emboline. "Trinity Capital's growth financing strengthens our ability to scale manufacturing, expand our team, and support the clinical and regulatory milestones that will bring this technology to patients worldwide."
This financing will support Emboline in preparing for the commercial launch of the Emboliner system while continuing to advance its platform of technologies aimed at reducing risk during minimally invasive heart procedures.
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than
About Emboline
Emboline, Inc. is a privately held medical technology company based in
For more information, visit emboline.com.
The Emboliner® device is currently investigational and is not available for commercial sale.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-20-million-in-growth-capital-to-emboline-inc-to-advance-interventional-heart-procedure-technology-302710135.html
SOURCE Trinity Capital Inc.